CA3102848A1 - Novel salts and crystals - Google Patents

Novel salts and crystals Download PDF

Info

Publication number
CA3102848A1
CA3102848A1 CA3102848A CA3102848A CA3102848A1 CA 3102848 A1 CA3102848 A1 CA 3102848A1 CA 3102848 A CA3102848 A CA 3102848A CA 3102848 A CA3102848 A CA 3102848A CA 3102848 A1 CA3102848 A1 CA 3102848A1
Authority
CA
Canada
Prior art keywords
salt
iti
less
free base
toluenesulfonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3102848A
Other languages
English (en)
French (fr)
Inventor
Peng Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CA3102848A1 publication Critical patent/CA3102848A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3102848A 2018-06-06 2019-06-06 Novel salts and crystals Pending CA3102848A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862681534P 2018-06-06 2018-06-06
US62/681,534 2018-06-06
PCT/US2019/035845 WO2019236889A1 (en) 2018-06-06 2019-06-06 Novel salts and crystals

Publications (1)

Publication Number Publication Date
CA3102848A1 true CA3102848A1 (en) 2019-12-12

Family

ID=68769581

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3102848A Pending CA3102848A1 (en) 2018-06-06 2019-06-06 Novel salts and crystals

Country Status (11)

Country Link
US (2) US20200157100A1 (enExample)
EP (1) EP3628007B1 (enExample)
JP (1) JP7476115B2 (enExample)
KR (1) KR102888393B1 (enExample)
CN (1) CN112384218B (enExample)
AU (1) AU2019280850C1 (enExample)
BR (1) BR112020024885A2 (enExample)
CA (1) CA3102848A1 (enExample)
IL (2) IL321985A (enExample)
MX (1) MX2020013116A (enExample)
WO (1) WO2019236889A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140146192A (ko) 2012-04-14 2014-12-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
PL3497104T3 (pl) 2016-08-09 2022-02-21 Teva Pharmaceuticals International Gmbh Postacie w stanie stałym soli ditosylanowej lumateperonu
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
US11440911B2 (en) 2017-09-26 2022-09-13 Intra-Cellular Therapies, Inc. Salts and crystals
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
CA3240552A1 (en) * 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
WO2021007245A1 (en) * 2019-07-07 2021-01-14 Intra-Cellular Therapies, Inc. Novel methods
US12478623B2 (en) 2019-09-25 2025-11-25 Intra-Cellular Therapies, Inc. Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
IL300886A (en) * 2020-09-04 2023-04-01 Intra Cellular Therapies Inc New salts, crystals and co-crystals
CN115120593A (zh) * 2021-03-26 2022-09-30 上海博志研新药物技术有限公司 卢美哌隆药用盐、制备方法、含其的药物组合物及应用
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
US20250352469A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices, and methods

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
EP0238059B1 (en) 1986-03-19 1993-06-16 Kumiai Chemical Industry Co., Ltd. 5H-1,3,4-Thiazole[3,2-a]pyrimidin-5-one derivatives and fungicidal compositions containing the same
DE3786365T2 (de) 1986-04-07 1993-10-21 Ihara Chemical Ind Co 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-on-Derivate und diese enthaltende Gartenbau- und landwirtschaftliche Fungizidmittel.
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
WO1999018057A1 (en) 1997-10-06 1999-04-15 Massachusetts Institute Of Technology Preparation of diaryl ether by condensation reactions
ATE229499T1 (de) 1998-02-26 2002-12-15 Massachusetts Inst Technology Metallkatalysierte arylierungen und vinylierungen von hydrazinen, hydrazonen, hydroxylaminen und oximen
US6235936B1 (en) 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
CA2336691C (en) 1998-07-10 2009-02-10 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
US20010008942A1 (en) 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
ATE277048T1 (de) 1999-06-15 2004-10-15 Bristol Myers Squibb Pharma Co Substituierte hetercyclisch kondensierte gamma carboline
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
SK7042003A3 (en) 2000-12-20 2004-07-07 Bristol Myers Squibb Co Substituted pyridoindoles as serotonin agonists and antagonists
KR20030092107A (ko) 2001-04-24 2003-12-03 메사추세츠 인스티튜트 오브 테크놀로지 탄소-헤테로원자 및 탄소-탄소 결합을 형성하는 구리-촉매방법
AU2003257062A1 (en) 2002-08-02 2004-02-23 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004056324A2 (en) 2002-12-19 2004-07-08 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
AR043242A1 (es) 2003-02-24 2005-07-20 Shell Int Research Preparacion y uso de una composicion de catalizador
ATE411980T1 (de) 2003-07-21 2008-11-15 Smithkline Beecham Corp (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl) l-phenylalanylü-2-pyrrolidincarbonitril-p- toluolsulfonsäuresalz und wasserfreie kristalline formen davon
JP2005259113A (ja) 2004-02-12 2005-09-22 Ricoh Co Ltd プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
ATE457989T1 (de) 2004-12-15 2010-03-15 Hoffmann La Roche Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
EP1848433A2 (en) 2005-01-25 2007-10-31 Celgene Corporation Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
US7645752B2 (en) 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
CN101484411A (zh) 2006-06-27 2009-07-15 桑多斯股份公司 盐的新制备方法
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
KR102107954B1 (ko) 2007-03-12 2020-05-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
MX2010001218A (es) 2007-08-01 2010-04-07 Medivation Neurology Inc Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
EP2250199B1 (en) 2008-02-07 2015-09-02 Merck Sharp & Dohme Corp. Engineered anti-tslpr antibodies
AU2009223701B2 (en) * 2008-03-12 2015-04-16 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines solid
EP3085231A1 (en) 2008-05-27 2016-10-26 Intra-Cellular Therapies, Inc. Method and compositions for sleep disorders and other disorders
CA2796756A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders
KR20140146192A (ko) 2012-04-14 2014-12-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US9708322B2 (en) 2013-03-15 2017-07-18 Intra-Cellular Therapies, Inc. Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
EP3436455A4 (en) * 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
PL3497104T3 (pl) 2016-08-09 2022-02-21 Teva Pharmaceuticals International Gmbh Postacie w stanie stałym soli ditosylanowej lumateperonu
WO2018106916A1 (en) 2016-12-07 2018-06-14 Concert Pharmaceuticals, Inc. Deuterated quinoxaline compounds
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
EP3609501A4 (en) 2017-04-10 2020-08-19 Dr. Reddy's Laboratories Limited AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE
US11440911B2 (en) 2017-09-26 2022-09-13 Intra-Cellular Therapies, Inc. Salts and crystals
EP3717484A4 (en) 2017-11-27 2021-08-04 Egis Gyógyszergyár Zrt. PROCESS FOR THE PRODUCTION OF LUMATEPERON AND ITS SALT
CA3240552A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis

Also Published As

Publication number Publication date
KR20210018440A (ko) 2021-02-17
MX2020013116A (es) 2021-05-12
IL279195B1 (en) 2025-08-01
CN112384218B (zh) 2024-04-26
WO2019236889A1 (en) 2019-12-12
JP7476115B2 (ja) 2024-04-30
IL321985A (en) 2025-09-01
US12195464B2 (en) 2025-01-14
EP3628007A4 (en) 2020-05-20
AU2019280850B2 (en) 2024-08-08
IL279195A (en) 2021-01-31
AU2019280850A1 (en) 2021-01-07
EP3628007B1 (en) 2023-05-03
JP2021527043A (ja) 2021-10-11
CN112384218A (zh) 2021-02-19
IL279195B2 (en) 2025-12-01
EP3628007A1 (en) 2020-04-01
US20200157100A1 (en) 2020-05-21
US20220281867A1 (en) 2022-09-08
KR102888393B1 (ko) 2025-11-18
BR112020024885A2 (pt) 2021-03-09
AU2019280850C1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
AU2019280850B2 (en) Novel salts and crystals
EP3436016B1 (en) Novel co-crystals
US10654854B2 (en) Salts and crystals of ITI-007
US12384783B2 (en) Salts and crystals
US20230312573A1 (en) Novel salts, crystals, and co-crystals
JP2020189856A (ja) ソフピロニウム臭化物の結晶形態及びその製造方法
HK40025629A (en) Novel salts and crystals
HK40025629B (en) Novel salts and crystals
HK40046696A (en) Novel salts and crystals
EP4713311A1 (en) Preparation of (s)-6-chloro-2,3,4,9-tetrahydro-1h-carbazole-1-carboxamide in enantiomerically enriched form by resolution process

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240605

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20241128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250417

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250417

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20250825

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20250825

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250825

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251229

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251229

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260128

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260415

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260415